Compare GameStop Corp. (GME) vs GSK plc (GSK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GameStop Corp. vs GSK plc — how do they compare? GameStop Corp. trades at $26.56 (market cap $12.75B), while GSK plc trades at $46.5 (market cap $91.88B). The key difference: GSK plc is far larger — about 7.2× GameStop Corp.'s market cap, and GSK plc pays a 3.9% dividend while GameStop Corp. pays none. Which is the better fit depends on your goals — on Pluang, investors hold GameStop Corp. for 62 Days and GSK plc for 93 Days on average.
| GME | GSK | |
|---|---|---|
Market Cap | $12.75B | $91.88B |
Volume | 13,026,993 | 7,730,529 |
Sector | Consumer Cyclical | Health |
52-Week High | $26.53 | $61.18 |
52-Week Low | $17.87 | $43.24 |
Typical Hold Time | 62 Days | 93 Days |
Enterprise Value | $12.03B | $111.88B |
Dividend Yield | — | 3.9% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GME trades at $25.28, up 2.85% today, with a bullish technical signal and strong insider buying. Recent earnings show mixed results, beating estimates in Q4 2025 and Q1 2026 but missing in Q2 2026. The company's balance sheet is robust with $4.77 billion in cash and low debt, while profitability improved significantly with a net income margin of 3.43% in 2025.
Outlook remains positive due to strong cash reserves and insider confidence, but risks include revenue decline and competitive pressures. Analyst consensus is cautious with only 16.67% buy ratings. The stock's valuation metrics suggest moderate pricing relative to earnings and sales.
GSK trades at $46.54, down 1.02% on the day, with a bearish technical signal from moving averages but oversold RSI readings. The company reported strong earnings beats in recent quarters, with Q2 2026 EPS of $1.36 exceeding the $1.27 estimate. Fundamentals show robust profitability with a 72.73% gross margin and 14.52% net margin, while valuation metrics like a P/E of 14.89 appear reasonable. Recent news highlights pipeline advancements, including a $750 million cancer therapy deal and strategic focus on oncology and cost savings.
The outlook is mixed; analyst consensus leans Hold (55.18%) with a minority Buy rating (31.03%), reflecting caution amid an approaching HIV patent cliff. Near-term support is at $45, with resistance at $47. Revenue growth to $33.2B in 2026 and a dividend of $0.45 per share offer stability, but execution risks and competitive pressures remain key watchpoints for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GameStop Corp.
Global Market Group Ltd. operates an Internet website that connects Chinese manufacturers with international buyers. The Company's customers can post company profiles and product information in standardized formats; post product listings; and trade leads.
Read more on GME →About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →
